Dengue vaccine passes FDA Advisory Committee hurdle

U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted this week on on the safety and effectiveness of Sanofi Pasteur's Dengvaxia(R) (Dengue Tetravalent Vaccine Live Attenuated). In people 9 to less than 17 years of age, the Committee voted favorably on effectiveness (13 to one) and safety (10 to four). In people ["]

The post Dengue vaccine passes FDA Advisory Committee hurdle appeared first on Outbreak News Today.